The most common adverse effects observed with<unk>  are diarrhea and nausea. In key clinical trials, moderate or severe diarrhea occurred in up to 27% of patients, and moderate/severe nausea in up to 16%. Other common adverse effects include abdominal pain, asthenia, headache, vomiting and, particularly in children, rash. Raised liver enzymes and hyperlipidemia (both hypertriglyceridemia and hypercholesterolemia) are also commonly observed during<unk>  treatment.<unk>  is anticipated to have varying degrees of interaction with other medications that are also CYP3A and/or P-gp substrates. People with a structural heart disease, preexisting conduction system abnormalities, ischaemic heart disease, or cardiomyopathies should use<unk>  with caution. On 8 March 2011 the U.S. Food and Drug Administration notified healthcare professionals of serious health problems that have been reported in premature babies receiving<unk>  oral solution, probably because of its propylene glycol content. They recommend the use should be avoided in premature babies.
Lopinavir/ritonavir
Atazanavir/ritonavir
Amprenavir
Abacavir/lamivudine
Ritonavir
Lamivudine/zidovudine
Lamivudine/tenofovir
Atazanavir/cobicistat